12:00 AM
Mar 11, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ATX-101: Additional Phase IIIb data

Additional data from the open-label, U.S. Phase IIIb Study ATX-101-11-26 trial in 165 patients aged 18 and older with submental fat who received subcutaneous microinjections of 2 mg/cm 2 ATX-101 given in 28-day cycles for up to 6 cycles showed that 87% of patients achieved a >=1-grade improvement in CR-SMFRS score and 83% of patients achieved a >=1-grade improvement in PR-SMFRS score from...

Read the full 291 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >